Polyanion induced fibril growth enables the development of a reproducible assay in solution for the screening of fibril interfering compounds, and the investigation of the prion nucleation site

被引:3
作者
Boshuizen, Ronald S.
Morbin, Michela
Mazzoleni, Giulia
Tagliavini, Fabrizio
Meloen, Rob H.
Langedijk, Johannes P. M.
机构
[1] Pepscan Therapeut BV, NL-8203 AB Lelystad, Netherlands
[2] Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy
[3] Univ Utrecht, Acad Biomed Ctr, Utrecht, Netherlands
来源
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2007年 / 14卷 / 03期
关键词
CJD; BSE; amyloid; prion; GAG; IN-VITRO CONVERSION; PROTEIN-FRAGMENT; INCUBATION PERIOD; ANTIPRION DRUGS; AMYLOID FIBRILS; DEXTRAN SULFATE; BINDING-SITES; CONGO RED; SCRAPIE; PEPTIDES;
D O I
10.1080/13506120701464628
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The misfolded conformer of the prion protein (PrP) that aggregates into fibrils is believed to be the pathogenic agent in transmissible spongiform encephalopathies. In order to find fibril interfering compounds a screening assay in solution would be the preferred format to approximate more closely to physical conditions and enable the performance of kinetic studies. However, such an assay is hampered by the high irreproducibility because of the stochastic nature of the fibril formation process. According to published fibril models, the fibrillar core may be composed of stacked parallel beta-strands. In these models positive charge repulsion may reduce the chance of favorable stacking and cause the irreproducibility in the fibril formation. This study shows that the charge compensation by polyanions induced a very strong fibril growth which made it possible to develop a highly reproducible fibril interference assay. The stimulating effect of the polyanions depended on the presence of the basic residues Lys(106), Lys(110) and His(111). The assay was validated by comparison of the 50% fibril inhibition levels of peptide huPrP106-126 by six tetracyclic compounds. With this new assay, the fibrillogenic core (GAAAAGAVVG) of peptide huPrP106-126 was determined and for the first time it was possible to test the inhibition potentials of peptide 15 120 analogues. Also it was found that variants of peptide huPrP106-126 with proline substitutions at positions Ala(115), Ala(120), or Val(122) inhibited the fibril formation of huPrP106-126.
引用
收藏
页码:205 / 219
页数:15
相关论文
共 61 条
[1]   Identification of the Cu2+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy [J].
Aronoff-Spencer, E ;
Burns, CS ;
Avdievich, NI ;
Gerfen, GJ ;
Peisach, J ;
Antholine, WE ;
Ball, HL ;
Cohen, FE ;
Prusiner, SB ;
Millhauser, GL .
BIOCHEMISTRY, 2000, 39 (45) :13760-13771
[2]   Pathway complexity of prion protein assembly into amyloid [J].
Baskakov, IV ;
Legname, G ;
Baldwin, MA ;
Prusiner, SB ;
Cohen, FE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21140-21148
[3]   Killing of prion-damaged neurones by microglia [J].
Bate, C ;
Reid, S ;
Williams, A .
NEUROREPORT, 2001, 12 (11) :2589-2594
[4]   Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets [J].
Bertsch, U ;
Winklhofer, KF ;
Hirschberger, T ;
Bieschke, J ;
Weber, P ;
Hartl, FU ;
Tavan, P ;
Tatzelt, M ;
Kretzschmar, HA ;
Giese, A .
JOURNAL OF VIROLOGY, 2005, 79 (12) :7785-7791
[5]   Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils [J].
Bocharova, OV ;
Breydo, L ;
Salnikov, VV ;
Baskakov, IV .
BIOCHEMISTRY, 2005, 44 (18) :6776-6787
[6]   In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrPSc [J].
Bocharova, OV ;
Breydo, L ;
Parfenov, AS ;
Salnikov, VV ;
Baskakov, IV .
JOURNAL OF MOLECULAR BIOLOGY, 2005, 346 (02) :645-659
[7]   An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds [J].
Boshuizen, RS ;
Langeveld, JPM ;
Salmona, M ;
Williams, A ;
Meloen, RH ;
Langedijk, JPM .
ANALYTICAL BIOCHEMISTRY, 2004, 333 (02) :372-380
[8]   Semiautomated cell-free conversion of prion protein: Applications for high-throughput screening of potential antiprion drugs [J].
Breydo, L ;
Bocharova, OV ;
Baskakov, IV .
ANALYTICAL BIOCHEMISTRY, 2005, 339 (01) :165-173
[9]   PRECISE TARGETING OF THE PATHOLOGY OF THE SIALOGLYCOPROTEIN, PRP, AND VACUOLAR DEGENERATION IN MOUSE SCRAPIE [J].
BRUCE, ME ;
MCBRIDE, PA ;
FARQUHAR, CF .
NEUROSCIENCE LETTERS, 1989, 102 (01) :1-6
[10]   MOLECULAR MODELING OF PROTEIN-GLYCOSAMINOGLYCAN INTERACTIONS [J].
CARDIN, AD ;
WEINTRAUB, HJR .
ARTERIOSCLEROSIS, 1989, 9 (01) :21-32